Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Infusional fluorouracil and weekly docetaxel as first-line therapy for gastric cancer with bone marrow metastasis and disseminated intravascular coagulation: A multi-center, phase II trial (Zhen Long).
Authors
Jian Xiao
Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
Jian Xiao , Xiaohui Zhai , Shanshan Li , Haibo Zhang , Yong Li , Jin Peng , Yisheng Huang , Lishuo Shi , Hailing Liu , Rongqin Zhang , Meiyu Hu , Xiaolin Pang , Xiaoru Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04547153
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 337)
DOI
10.1200/JCO.2024.42.3_suppl.337
Abstract #
337
Poster Bd #
F17
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer.
First Author: E. Van Cutsem
Poster
2018 ASCO Annual Meeting
Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.
First Author: Feng Wang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A modified triplet combination of docetaxel, oxaliplatin, and fluorouracil for gastric cancer (GC) with peritoneal carcinomatosis (PC) and inoperable malignant bowel obstruction (MBO): A multi-center, non-randomized, three-cohort, phase II trial (Zhen Jing).
First Author: Jian Xiao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama